BCLC 2024 Staging System for Liver Cancer: Prognosis, Treatment Allocation, and Clinical Decision-Making
The BCLC 2024 system is the reference staging framework for hepatocellular carcinoma — integrating tumor burden, liver function, and performance status to guide personalized treatment.
What Is the BCLC 2024 System?
BCLC is the standard staging system used worldwide to classify hepatocellular carcinoma and guide treatment decisions.
BCLC 2024 is the standard staging system used to classify hepatocellular carcinoma and guide treatment decisions. It combines tumor burden, liver function, and performance status to estimate prognosis and match patients with the most appropriate therapy.
The 2024 update strengthens the role of personalized decision-making, multidisciplinary review, and treatment selection across surgical, locoregional, and systemic options. It remains the most widely used system for HCC prognosis and treatment selection because of its strength in linking staging to evidence-based management.
Why BCLC Matters
Unlike TNM staging which only describes anatomical tumor extent, BCLC integrates liver reserve (Child-Pugh, ALBI) and functional status (ECOG) — factors that often determine survival more than tumor size in HCC patients.
What Changed in the 2024 Update?
The 2024 update refines treatment allocation and strengthens the role of multidisciplinary decision-making.
Key Updates in BCLC 2024
Stage B refinement: Subclassification into B1, B2, B3 based on tumor burden and liver function to distinguish patients who benefit from TACE versus those requiring upfront systemic therapy.
Immunotherapy integration: First-line atezolizumab-bevacizumab is now standard for Stage C patients with preserved liver function.
Expanded treatment options: Downstaging criteria broadened for select patients, allowing potential transition from palliative to curative pathways.
Multidisciplinary emphasis: Treatment decisions should be made in multidisciplinary tumor boards rather than by staging alone.
BCLC 2024 Stages and Treatment Allocation
Five stages (0, A, B, C, D) with evidence-based treatment recommendations
Stage 0 — Very Early HCC
Single tumor ≤2 cm, Child-Pugh A, ECOG 0
- Curative intent: Resection or local ablation
- No portal hypertension required for ablation
- Excellent long-term survival
Stage A — Early HCC
Single tumor or ≤3 nodules ≤3 cm, Child-Pugh A-B, ECOG 0
- Options: Resection, ablation, or liver transplant
- Milan criteria for transplant candidacy
- Potentially curable with appropriate therapy
Stage B — Intermediate HCC
Multinodular, Child-Pugh A-B, ECOG 0
- Subclassified into B1, B2, B3
- First-line: TACE for selected patients
- Systemic therapy if TACE-untreatable
Stage C — Advanced HCC
Portal invasion or extrahepatic spread, Child-Pugh A-B, ECOG 0-2
- First-line: Atezolizumab + Bevacizumab
- Alternatives: Durvalumab + Tremelimumab
- Second-line: Sorafenib, Lenvatinib, Cabozantinib
Stage D — End-Stage HCC
Child-Pugh C or ECOG 3-4
- Best supportive care
- Symptom management and palliative care
- Limited survival — focus on quality of life
BCLC Stage B: Why Subclassification Matters
Stage B is the most heterogeneous stage in HCC — not all intermediate-stage patients should receive the same treatment.
Stage B HCC encompasses a wide range of tumor burdens and liver function profiles. The 2024 update emphasizes subclassification into B1 (low tumor burden), B2 (intermediate), and B3 (high tumor burden) to avoid undertreating or overtreating patients.
Patients with B1 disease may benefit from TACE alone, while those with B3 — extensive bilobar involvement or large tumor volume — are often better served with upfront systemic therapy. This concept of "TACE-untreatable" progression is critical: continuing TACE when tumors have become refractory can worsen liver function and delay effective systemic treatment.
Stage B Decision Factors
Tumor burden: Number, size, and distribution of nodules
Liver reserve: Child-Pugh score, ALBI grade
Feasibility of locoregional therapy: TACE accessibility, portal vein patency
Response assessment: When to switch from TACE to systemic therapy
Prognostic Factors Used in BCLC 2024
BCLC integrates three categories of variables to determine stage and guide treatment.
| Factor Category | Variables Assessed | Role in Staging |
|---|---|---|
| Tumor Burden | Number of nodules, size, vascular invasion, extrahepatic spread | Distinguishes Stage 0/A from B/C |
| Liver Function | Child-Pugh score, albumin-bilirubin (ALBI) grade, portal hypertension | Determines treatment eligibility and Stage D assignment |
| Performance Status | ECOG scale (0 to 4) | ECOG ≥3 defines Stage D regardless of tumor extent |
| Tumor Biology (Emerging) | Molecular subtypes, ctDNA, response to prior therapy | Growing role in refining prognosis within stages |
When BCLC Should Be Combined with Multidisciplinary Review
Staging alone is not enough — clinical decisions benefit from tumor board discussion.
Suspected HCC → Confirmed Diagnosis
Imaging (CT/MRI with contrast) and/or biopsy confirm HCC. Multiphasic imaging defines tumor characteristics, while blood tests assess liver function and AFP/PIVKA-II levels. Accurate diagnosis is the prerequisite for correct staging.
Newly Diagnosed HCC → Staging Assignment
Once HCC is confirmed, BCLC stage is determined by tumor burden, liver function, and performance status. This stage guides the first treatment recommendation but should be interpreted alongside clinical judgment — not as a rigid rule.
Treatment Selection → Therapy Allocation
BCLC links each stage to a preferred treatment pathway. However, patients at the border between stages (e.g., B vs C) or with multiple comorbidities benefit from multidisciplinary tumor board discussion to personalize the approach.
Second Opinion → When Additional Review Is Useful
Patients with complex presentations, uncertain staging, or who have progressed on first-line therapy often benefit from an expert second opinion. Review of imaging, pathology, and treatment history can identify alternative pathways — including downstaging, clinical trials, or access to therapies available in other countries.
Frequently Asked Questions About BCLC 2024
The Barcelona Clinic Liver Cancer (BCLC) 2024 system is the standard staging framework for hepatocellular carcinoma. It combines tumor burden, liver function, and performance status to estimate prognosis and guide treatment allocation across five stages.
BCLC stage is determined by evaluating three core factors: tumor characteristics (number, size, vascular invasion, extrahepatic spread), liver function (Child-Pugh score, albumin-bilirubin), and performance status (ECOG scale).
BCLC Stage A refers to early, solitary tumors or up to 3 nodules ≤3 cm with preserved liver function. Stage B is intermediate, multinodular disease. Stage A is potentially curable; Stage B typically requires locoregional or systemic therapy.
Stage B is the most heterogeneous stage. Subclassification into B1, B2, B3 based on tumor burden helps refine treatment decisions — some patients benefit from TACE, others require systemic therapy if tumor burden exceeds the 'TACE-untreatable' threshold.
No. TNM staging classifies only the anatomical tumor extent. BCLC additionally integrates liver function and performance status, making it more practical for treatment allocation in HCC, where liver reserve often determines prognosis more than tumor size.
Yes. Successful downstaging — through TACE, systemic therapy, or radiation — can allow patients initially classified as Stage B or C to become eligible for curative treatments like resection or transplant. This concept, called 'stage migration,' is an important part of modern HCC management.
A second opinion is valuable when staging is uncertain, when patients fall between stages, when first-line therapy has failed, or when considering participation in clinical trials. Expert multidisciplinary review can identify treatment options not available at the patient's local center.
Multiphasic contrast-enhanced CT or MRI is essential for BCLC staging. Imaging determines tumor number, size, vascular invasion, and extrahepatic spread — the tumor burden variables that are a core component of the BCLC classification.
Need Expert BCLC Staging Review?
Submit your case for a multidisciplinary assessment of your BCLC stage and treatment options — including access to therapies across our global network.